{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=4", "query": { "condition": "Relapsed/Refractory Lymphomas", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1803, "total_pages": 181, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Lymphomas&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T02:50:34.260Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT02890368", "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Mycosis Fungoides", "Melanoma", "Merkel-cell Carcinoma", "Squamous Cell Carcinoma", "Breast Carcinoma", "Human Papillomavirus-Related Malignant Neoplasm", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "TTI-621 Monotherapy", "type": "DRUG" }, { "name": "TTI-621 + PD-1/PD-L1 Inhibitor", "type": "DRUG" }, { "name": "TTI-621 + pegylated interferon-α2a", "type": "DRUG" }, { "name": "TTI-621 + T-Vec", "type": "OTHER" }, { "name": "TTI-621 + radiation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2016-09", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2023-04-05", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 7, "location_summary": "Duarte, California • New York, New York • Portland, Oregon + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890368" }, { "nct_id": "NCT05162976", "title": "CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oral Azacitidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-01-03", "completion_date": "2027-04-27", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05162976" }, { "nct_id": "NCT05798897", "title": "Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma, Adult", "Non-Hodgkin Lymphoma, Refractory", "Non-Hodgkin Lymphoma, Relapsed", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Hodgkin Lymphoma, Adult", "Hodgkin's Lymphoma, Relapsed, Adult" ], "interventions": [ { "name": "MT-601", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 79, "start_date": "2023-01-02", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 7, "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798897" }, { "nct_id": "NCT03736616", "title": "Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Autologous HSCT", "type": "OTHER" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 47, "start_date": "2019-08-16", "completion_date": "2023-09", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03736616" }, { "nct_id": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933985" }, { "nct_id": "NCT00079443", "title": "FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-01", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079443" }, { "nct_id": "NCT00423826", "title": "Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": null, "start_date": "2007-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-02-29", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423826" }, { "nct_id": "NCT01148108", "title": "Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "B Cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Canfosfamide HCl for injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-06", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-03-15", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148108" }, { "nct_id": "NCT05537766", "title": "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Waldenstrom Macroglobulinemia", "Relapsed/Refractory Richter Transformation", "Relapsed/Refractory Burkitt Lymphoma", "Relapsed/Refractory Hairy Cell Leukemia" ], "interventions": [ { "name": "Brexucabtagene Autoleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2022-11-01", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-11T02:50:34.260Z", "location_count": 12, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537766" } ] }